In recent years, with the continuous growth of the domestic economy and the maturity of Internet technology, coupled with the in-depth promotion of pharmaceutical reform, the introduction of relevant policies has further accelerated the transfer of the drug sales market from inside the hospital to outside the hospital. Ark Yunkang Holdings*** hereinafter referred to as Ark Yunkang) has seized the market development opportunity and opened a new ecological model of H2H (hospital to home, that is, from hospital to home) smart medical care with scientific and technological innovation. According to the prospectus, Ark Yunkang focuses on chronic disease management business, and its brand Ark Jianke is committed to meeting the huge and unmet needs of chronic disease patients in China, and Ark Yunkang is co-sponsored by Citigroup, UBS Group and ABC International.
In the field of chronic diseases, pharmaceutical e-commerce plays an important role as an important supplement to patients' drug purchase channels. However, in addition to providing drug sales services, it is also important to focus on the patient's condition. According to the prospectus, for chronic disease management, Ark Yunkang has developed three major businesses, including comprehensive medical services, online retail pharmacy services, customized content and marketing solutions, to achieve a closed loop of Internet medical services supported by Ark Jianke Internet Hospital, a distributed chronic disease management service center combining devices and clouds, a new health matrix and a nationally renowned pharmaceutical e-commerce platform.
In addition, the Ark Yunkang prospectus disclosed that as of December 31, 2023, Ark Jianke cooperated with more than 760 pharmaceutical companies, including multinational companies and large domestic pharmaceutical companies, purchased from more than 1,400 ** manufacturers and provided more than 212,000 drug SKUs. These partnerships provide Ark Yunkang with abundant pharmaceutical resources and further consolidate its dominant position in the field of digital chronic disease management.
It is worth paying attention to investors that Ark Yunkang's earnings expectations are improving. According to the prospectus disclosed by Ark Yunkang, thanks to the increasing willingness of loyal users to pay, Ark Yunkang's revenue continues to grow, and in 2021, 2022 and 2023, the company's revenue will be RMB 175.9 billion yuan, 220.4 billion yuan, 243.4 billion yuan. Gross profit also continued to increase, which was RMB22 billion yuan, 38.1 billion yuan, 48.7 billion yuan.
For Ark Yunkang to sprint to Hong Kong stocks again, some industry insiders pointed out that Ark Yunkang is expected to achieve good development after listing on the Hong Kong Stock Exchange. This time to the Hong Kong Stock Exchange, Ark Yunkang is full of confidence. Ark Yunkang said that this listing will bring new changes to chronic disease management services, and firmly believes that Ark Yunkang will continue to play an important role in the field of chronic disease management and continue to make efforts to protect people's health.